search

Active clinical trials for "Mastocytosis, Systemic"

Results 31-40 of 46

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent...

Indolent Systemic Mastocytosis

Background: Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms. Researchers think the drug sarilumab could help. Objective: To see if sarilumab is a safe and effective treatment for people with ISM. Eligibility: Adults ages 18-75 with ISM who are enrolled in NIH study 02-I-0277 Design: Participants will be screened with: Physical exam Medical history Blood and urine tests Questionnaires Bone marrow removed by a needle inserted into the hip bone Ultrasound of the abdomen Photographs of the skin Participants will repeat some screening tests at study visits. Participants will have a baseline visit in the hospital for 3 days. They will: Be assigned to get either the study drug or a placebo. They will not know which one they get. Have a skin punch biopsy: An instrument will remove a small piece of skin. Get their first drug dose injected under their skin Participants will keep a side effect and medication diary during the study. Participants will visit the clinic to get a drug dose every 2 weeks, for a total of 8 doses. Participants will have a visit 2 weeks after their final dose. It will last up to 2 days. Participants will have another visit 12 weeks later. Participants may then continue this study for 1 more year. Those who continue will get sarilumab, even if they previously got the placebo, every 2 weeks. They will have visits every 6 weeks, and then every 3 months.

Completed36 enrollment criteria

Treatment of Indolent Systemic Mastocytosis With PA101

MastocytosisSystemic Mastocytosis1 more

This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM). The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.

Completed19 enrollment criteria

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Non Neoplastic ConditionPrecancerous Condition

RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.

Completed24 enrollment criteria

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

LeukemiaSystemic Mastocytosis

Primary Objective: 1. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: To assess the safety of ONTAK in SM patients. To evaluate the time to progression and duration of response following treatment with ONTAK.

Completed11 enrollment criteria

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Systemic MastocytosisAggressive (ASM)3 more

The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)

Completed37 enrollment criteria

Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis

Systemic Mastocytosis

The hypothesis of the study is that Bone Marrow Tryptase (MT) level is a diagnostic marker of Systemic Mastocytosis (SM). Determination of the bone marrow tryptase in Bone Marrow Aspirate (BMA) could be a new diagnostic criteria for systemic mastocytosis with sensitivity close to 100% and a low false negative rate. This new test could be useful to improve the ability to diagnose accurately systemic mastocytosis (in particular the indolent forms). Because of its limited invasiveness compared to bone marrow biopsy, it could also be considered as a test performed before bone marrow biopsy. Only patients with high bone marrow tryptase would then undergo bone marrow biopsy. In the future and if validated by this study, bone marrow tryptase could be a useful marker of mast cell load and help to monitor the efficacy of treatment in systemic mastocytosis.

Completed4 enrollment criteria

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Acute Biphenotypic LeukemiaAcute Leukemia15 more

This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Withdrawn59 enrollment criteria

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Systemic Mastocytosis

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.

Unknown status9 enrollment criteria

Midostaurin in Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

Rationale: Patients with indolent or smoldering systemic mastocytosis can have severe disabling symptoms. Almost all patients have fatigue, a compromised quality of life, hampering normal functioning. Because this form of mastocytosis is not considered life-threatening, mast cell eradication has never been applied and patients receive only symptomatic therapy with histamine blockers. Midostaurin, a c-KIT inhibitor has shown activity regarding symptom control and decrease of malignant mast cells in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia

Unknown status16 enrollment criteria

Evaluation of Response of Dasatinib to Treat Mastocytosis

Systemic Mastocytosis

This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).

Unknown status39 enrollment criteria
1...345

Need Help? Contact our team!


We'll reach out to this number within 24 hrs